REIT - Healthcare Facilities · NYSE
Healthpeak Properties, Inc. is a bank, insurer, or real estate company. A standard discounted cash flow model values a business on its free cash flow, but for these companies free cash flow is not a clean measure of value. Banks and insurers are valued on book value, return on equity, and a price-to-earnings multiple; REITs are valued on funds from operations (FFO) and dividends, not free cash flow. Running a free cash flow DCF here would produce a misleading number, so none is shown.
Current Price
$17.10
COMPETITIVE MOAT
INVESTMENT RISKS
Healthpeak Properties, Inc., an S&P 500 constituent, operates as a fully integrated real estate investment trust (REIT). The company specializes in the acquisition and development of premium properties across three private-pay healthcare segments: Life Science, Medical Office, and Senior Housing. This focus is meticulously crafted to deliver stability amidst the cyclical nature of the industry. Healthpeak leverages its profound expertise in the healthcare property market, coupled with an ambitious outlook for sustained, long-term expansion.
As a REIT, Healthpeak Properties, Inc. must pay out most of its income as dividends and carries heavy non-cash depreciation on its buildings, so reported net income and free cash flow understate how much the properties actually earn. A DCF built on those figures misses the real cash the portfolio produces. A REIT is read on funds from operations and dividends instead.
Healthpeak Properties, Inc. is better read through price-to-FFO, which uses funds from operations, and the dividend yield rather than price-to-earnings, together with occupancy and the quality of its properties. The PEAK PE view is a starting point, but multiples based on funds from operations fit a REIT better.
DCF and P/E value PEAK with different methods and assumptions, so the two conclusions can differ. Compare the P/E fair value.
Price as of 2024-03-01. Financial data from Financial Modeling Prep (trailing twelve months) · Valuation methodology by Charlie Wang.
This is an estimate, not investment advice.